Eyestem’s new cell therapy for Dry AMD, showing promising safety and vision improvement in Phase 1 trials. A new hope for treating geographic atrophy.
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of STELARA® (ustekinumab) [Read More…]
Eli Lilly and Company declared today that Zepbound (tirzepatide), a popular weight-loss drug, will soon be offered in single-dose vials via LillyDirect Self Pay Pharmacy [Read More…]
Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
Johnson & Johnson reported encouraging new results from a Phase 1b trial that found its experimental oral medicine, bleximenib, given with the routine treatment regimen [Read More…]
In an important milestone for the treatment of hepatitis C, AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion of MAVYRET® (glecaprevir/pibrentasvir), its pangenotypic, oral, direct-acting antiviral (DAA) therapy. The new indication [Read More…]
Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March. Advancements in Immune Thrombocytopenia (ITP) Sanofi shared Phase 3 LUNA [Read More…]
